山东省立医院
Shandong Provincial Hospital
在本站收录的 53 种疾病中,这家医院列在其中 28 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
山东省立医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma29 篇牵头论文牵头 2 项开放试验
- 肝细胞癌Hepatocellular carcinoma76 篇牵头论文
- 胃癌Stomach cancer59 篇牵头论文
- 肝母细胞瘤Hepatoblastoma3 篇牵头论文
- 骨肉瘤Osteosarcoma7 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour5 篇牵头论文
- 神经母细胞瘤Neuroblastoma3 篇牵头论文
- 尤文肉瘤Ewing sarcoma0 篇牵头论文
- 多发性骨髓瘤Multiple myeloma6 篇牵头论文
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia2 篇牵头论文
- 再生障碍性贫血Aplastic anaemia4 篇牵头论文
- 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome1 篇牵头论文
- 范可尼贫血Fanconi anaemia3 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder2 篇牵头论文
- 重症肌无力Myasthenia gravis3 篇牵头论文
- 肝豆状核变性Wilson disease2 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis8 篇牵头论文
- 大动脉炎Takayasu arteritis1 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis3 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis2 篇牵头论文
- 法布雷病Fabry disease0 篇牵头论文
- 庞贝病Pompe disease1 篇牵头论文
- 白塞病Behçet disease2 篇牵头论文
- IgA 肾病IgA nephropathy3 篇牵头论文
- 成骨不全症Osteogenesis imperfecta6 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文
- 先天性巨结肠Hirschsprung disease3 篇牵头论文
- 遗传性大疱性表皮松解症Inherited epidermolysis bullosa1 篇牵头论文
未列出的收录疾病:鼻咽癌、视网膜母细胞瘤、脊索瘤、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、血栓性血小板减少性紫癜、IgG4相关性疾病、烟雾病、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、原发性硬化性胆管炎、先天性膈疝、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 29 篇,占 1.0%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 6 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Neoadjuvant QL1706 Therapy for ESCC
- 分期
- II期
- 开始
- 2025-04
- 登记号
- NCT06908382
年龄 18 岁 至 75 岁(登记的条件)
牵头:山东省立医院济南
- 正在招募Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
- 分期
- 未注明
- 开始
- 2023-05
- 登记号
- NCT07549100
年龄 18 岁 至 75 岁(登记的条件)
牵头:山东省立医院济南
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文29
- Overexpression of YAP confers radioresistance to esophageal cancer by altering the tumor microenvironment.
- Inhibition of esophageal squamous cell carcinoma progression by MIR210HG and activation of the P53 signaling pathway to promote apoptosis and autophagy.
- Efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a prospective cohort study with propensity-score matching.
- SLC25A1 promotes lymph node metastasis of esophageal squamous cell carcinoma by regulating lipid metabolism.
- Deciphering the generation of heterogeneity in esophageal squamous cell carcinoma metastasis via single-cell multiomics analysis.
- SOX2 drives esophageal squamous carcinoma by reprogramming lipid metabolism and histone acetylation landscape.
- m6A reader IGF2BP2 mediates paclitaxel resistance in esophageal squamous cell carcinoma via FOXM1 mRNA stabilization.
- HOXA5 Derives the Malignant Progression and Cisplatin Resistance of Esophageal Squamous Cell Carcinoma by Regulating USP18-Mediated IFI27 Deubiquitination.
- LINC00963 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma by Interacting with miR-10a to Upregulate SKA1 Expression.
- MUC1 promotes lymph node metastasis in esophageal squamous cell carcinoma by downregulating DNAJB6 expression.
- MiR-92a-2-5p suppresses esophageal squamous cell carcinoma cell proliferation and invasion by targeting PRDX2.
- VBP1 promotes tumor proliferation as a part of the hypoxia-related signature in esophageal squamous cell carcinoma.
- T cell-related circRNA pairs to predict prognosis of patients with esophageal squamous cell carcinoma.
- The m6A reader IGF2BP2 promotes ESCC progression by stabilizing HDGF mRNA.
- Impact of Mitophagy-Related Genes on the Diagnosis and Development of Esophageal Squamous Cell Carcinoma via Single-Cell RNA-seq Analysis and Machine Learning Algorithms.
- Construction of a Novel Mitochondria-Associated Gene Model for Assessing ESCC Immune Microenvironment and Predicting Survival.
- Exosomes loaded with the anti-cancer molecule mir-1-3p inhibit intrapulmonary colonization and growth of human esophageal squamous carcinoma cells.
- CT-based delta-radiomics nomogram to predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma patients.
- NUPR1 induces autophagy and promotes the progression of Esophageal squamous cell carcinoma via the MAPK-mTOR pathway.
- The Function of lncRNA LINC00997 as a Diagnostic Marker in the Progression of Esophageal Squamous Cell Carcinoma.
- RNF106 aggravates esophageal squamous cell carcinoma progression through LATS2/YAP axis.
- CUL4B enhances the malignant phenotype of esophageal squamous cell carcinoma by suppressing TGFBR3 expression.
- Single-cell mapping of N6-methyladenosine in esophageal squamous cell carcinoma and exploration of the risk model for immune infiltration.
- A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis.
- Hypoxia-inducible factor-2α promotes EMT in esophageal squamous cell carcinoma through the Notch pathway.
- Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD-L1, IDO, TIM-3, FOXP3+ and CD8 expressions in patients with advanced esophageal squamous cell carcinoma.
- Downregulation of fibulin-4 inhibits autophagy and promotes the sensitivity of esophageal squamous cell carcinoma cells to apatinib by activating the Akt-mTOR signaling pathway.
- Knockdown of DEAD-box 51 inhibits tumor growth of esophageal squamous cell carcinoma via the PI3K/AKT pathway.
- EPB41L5 promotes EMT through the ERK/p38 MAPK signaling pathway in esophageal squamous cell carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
PubMed 以外找到的论文(未计入)17
- Study on the effect of molecular regulation on oxaliplatin resistance and macrophage polarization in esophageal squamous cell carcinoma based on the multiomics bioinformatic analysis and experimental verification
- 103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
- 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies
- Abstract 5208: Dynamic changes in circulating tumor DNA and T cell receptor repertoire predict disease progression in patients with unresectable esophageal squamous cell carcinoma
- Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Construction of a survival model for Esophageal Squamous Carcinoma and prediction of potential treatment with herbal medicine
- Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).
- The Role of CT-Based Radiomics Nomogram in Differential Diagnosis of Immune Checkpoint Inhibitor-Related Pneumonitis from Radiation Pneumonitis for Patients with ESCC
- YAP1-TEAD4-DKK1 is an effective target for inhibiting radiation resistance in esophageal squamous carcinoma and activation of the pathway may be related to poor prognosis of patients
- Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma
- MiR-4739 inhibits the malignant behavior of esophageal squamous cell carcinoma cells via the homeobox C10/vascular endothelial growth factor A/phosphatidylinositol 3-kinase/AKT pathway
- 166TiP Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed surgery for locally advanced esophageal squamous cell carcinoma: Protocol for a multi-center, prospective, randomized-controlled, phas
- MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 76 篇,占 0.5%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 6 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。
这些数字背后的记录
牵头的论文76
- Predictive model development and validation of functional liver imaging score for prognosis of patients with hepatocellular carcinoma after surgical resection: a multicenter study.
- Nomogram to Predict Tumor Remnant of Small Hepatocellular Carcinoma after Microwave Ablation.
- Artificial intelligence-assisted platform performs high detection ability of hepatocellular carcinoma in CT images: an external clinical validation study.
- The E3 ubiquitin ligase TRIM56 promotes aggregation and activation of Src protein through Lys63-linked polyubiquitination in hepatocellular carcinoma.
- MiR-101-3p targets the PI3K-AKT signaling pathway via Birc5 to inhibit invasion, proliferation, and epithelial-mesenchymal transition in hepatocellular carcinoma.
- Novel histone modifications and liver cancer: emerging frontiers in epigenetic regulation.
- Adrenal crisis occurring after the application of immune checkpoint inhibitors in a hepatitis B - related hepatocellular carcinoma patient: case report and literature review.
- Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma in patients with decompensated cirrhosis.
- Radiofrequency Ablation and Immunotherapy: Orchestrating the Immune Microenvironment for Improved Hepatocellular Carcinoma Control.
- Quality and Reliability of Transarterial Chemoembolization Videos on TikTok and Bilibili: Cross-Sectional Content Analysis Study.
- Establishment and Validation of Diagnostic Model of Microvascular Invasion in Solitary Hepatocellular Carcinoma.
- Mechanism of METTL14 regulates HBV-HCC malignant progression by mediating m6A modification of FOXP3 and thus transcriptional activation of ALDOB.
- Single-cell RNA sequencing reveals a B cell-related immunosuppressive landscape and a potential suppressor in hepatocellular carcinoma.
- Microwave Ablation Versus Surgical Resection for Small (≤3 cm) Hepatocellular Carcinoma in Older Patients: A Propensity Score Matching Analysis.
- Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway.
- RBBP6-induced destabilization of FOXP3 promotes glucose metabolism and malignant progression of HBV-related hepatocellular carcinoma.
- The molecular receptor NKBB enhances the persistence and anti-hepatocellular carcinoma activity of GPC3 CAR-T cells.
- Nanoparticle conjugation of ginsenoside Rh2 enhanced antitumor efficacy on hepatocellular carcinoma.
- Comprehensive bioinformatics analysis of MEX3 family genes in hepatocellular carcinoma.
- Rapid and portable detection of hepatocellular carcinoma marker alpha-fetoprotein using a droplet evaporation-based biosensor.
- A Comparative Study of Antitumor Immunity Induced by Radiofrequency Microwave and Cryoablation in Hepatocellular Carcinoma.
- Treatment and prognosis study of spontaneous rupture hemorrhage in hepatocellular carcinoma: Recommendations for adding the A1 stage to the BCLC staging system.
- Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets.
- Microwave ablation versus laparoscopic resection for hepatocellular carcinoma in patients with clinically significant portal hypertension: a propensity score-matched study of postoperative liver decompensation.
- Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.
- Attenuation of pro-tumorigenic senescent secretory phenotype by StN, a novel derivative of stevioside, potentiates its inhibitory activity on hepatocellular carcinoma.
- Investigation on the mechanisms of scorpion venom in hepatocellular carcinoma model mice via untargeted metabolomics profiling.
- Nanotechnology for the Diagnosis and Treatment of Liver Cancer.
- Identification of a novel molecular classification for hepatocellular carcinoma based on disulfideptosis-related genes and its potential prognostic significance.
- Prognostic Signature Constructed of Seven Ferroptosis-Related lncRNAs Predicts the Prognosis of HBV-Related HCC.
- CT-based radiomics nomogram to predict proliferative hepatocellular carcinoma and explore the tumor microenvironment.
- Expression of interleukin-8 and integrin β3 predicts prognosis of patients with hepatocellular carcinoma after hepatectomy.
- Mitochondrial ribosomal protein L12 potentiates hepatocellular carcinoma by regulating mitochondrial biogenesis and metabolic reprogramming.
- TEAD2 Promotes Hepatocellular Carcinoma Development and Sorafenib Resistance via TAK1 Transcriptional Activation.
- From NAFLD to HCC: Advances in noninvasive diagnosis.
- Silencing of RAB42 down-regulated PD-L1 expression to inhibit the immune escape of hepatocellular carcinoma cells through inhibiting the E2F signaling pathway.
- Microwave ablation versus radiofrequency ablation as bridge therapy in potentially transplantable patients with single HCC ≤ 3 cm: A propensity score-matched study.
- Microwave ablation versus surgical resection for subcapsular hepatocellular carcinoma: a propensity score-matched study of long-term therapeutic outcomes.
- Development and validation of a mitochondrial energy metabolism-related risk model in hepatocellular carcinoma.
- Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma.
- Efficacy and safety of apatinib and transcatheter arterial chemoembolization as second-line therapy for advanced hepatocellular carcinoma: A retrospective cohort study.
- Multifaceted roles of aerobic glycolysis and oxidative phosphorylation in hepatocellular carcinoma.
- Perfusion parameters of triphasic computed tomography hold preoperative prediction value for microvascular invasion in hepatocellular carcinoma.
- Exosome-mediated transfer of circRNA563 promoting hepatocellular carcinoma by targeting the microRNA148a-3p/metal-regulatory transcription factor-1 pathway.
- Drug-eluting bead transarterial chemoembolization with medium-sized versus small-sized CalliSpheres microspheres in unresectable primary liver cancer.
- Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma.
- RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
- An Elevated Neutrophil-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Liver Cancer after Interventional Treatments.
- Cleavage stimulation factor 2 promotes malignant progression of liver hepatocellular carcinoma by activating phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin pathway.
- EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli.
- Intrahepatic Splenosis Mimicking Hepatocellular Carcinoma.
- Multi-phase contrast-enhanced magnetic resonance image-based radiomics-combined machine learning reveals microscopic ultra-early hepatocellular carcinoma lesions.
- Quantitative parameters obtained from gadobenate dimeglumine-enhanced MRI at the hepatobiliary phase can predict post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma.
- Single-direction diffusion-weighted imaging may be a simple complementary sequence for evaluating fetal corpus callosum.
- The value of gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase for predicting post-hepatectomy liver failure in HCC patients.
- Microwave ablation versus radiofrequency ablation for subcapsular hepatocellular carcinoma: a propensity score-matched study.
- Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis.
- Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression.
- Sirolimus or Everolimus Improves Survival After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
- CircRNA hsa_circ_0110102 inhibited macrophage activation and hepatocellular carcinoma progression via miR-580-5p/PPARα/CCL2 pathway.
- Impact of Postoperative Complications on Long-Term Survival After Resection of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
- ASO Author Reflections: Impact of Postoperative Complications on Long-Term Survival After Resection of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
- MKL1 regulates hepatocellular carcinoma cell proliferation, migration and apoptosis via the COMPASS complex and NF-κB signaling.
- Abnormal Expression of Centromere Protein U Is Associated with Hepatocellular Cancer Progression.
- COPB2: A Novel Prognostic Biomarker That Affects Progression of HCC.
- Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.
- A novel four-gene of iron metabolism-related and methylated for prognosis prediction of hepatocellular carcinoma.
- A prediction model of major complications after radiofrequency ablation for recurrent hepatocellular carcinoma patients.
- Microwave ablation versus radiofrequency ablation for perivascular hepatocellular carcinoma: a propensity score analysis.
- MiR-222-3p induced by hepatitis B virus promotes the proliferation and inhibits apoptosis in hepatocellular carcinoma by upregulating THBS1.
- Liver resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis.
- A nomogram to predict microvascular invasion in early hepatocellular carcinoma.
- Role of Matrix Metallopeptidase 12 in the Development of Hepatocellular Carcinoma.
- Repeated postoperative adjuvant TACE after curative hepatectomy improves outcomes of patients with HCC.
- Prognostic significance of preoperative systemic inflammatory biomarkers in patients with hepatocellular carcinoma after microwave ablation and establishment of a nomogram.
- Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B.
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational Study
- To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer
- Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 59 篇,占 0.6%。
- 牵头的开放试验
- 0
- 正在或即将招募
济南有 8 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- 分期
- III期
- 开始
- 2026-12
- 登记号
- NCT07789184
年龄 18 岁 至 70 岁(登记的条件)
牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛
- 正在招募First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
- 分期
- II期
- 开始
- 2024-10
- 登记号
- NCT06730373
年龄 18 岁 至 75 岁(登记的条件)
牵头:山东大学齐鲁医院;另有 7 家列出的医院为研究中心临沂、济南、淄博、烟台、郑州、青岛
- 即将招募Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
- 分期
- 不分期
- 开始
- 2026-10
- 登记号
- NCT07828899
年龄 18 岁 至 85 岁(登记的条件)
牵头:温州医科大学附属第一医院;另有 2 家列出的医院为研究中心济南、温州、石家庄
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文59
- ALKBH5-mediated m6A demethylation of TXNDC5 drives malignant progression in gastric cancer.
- Metabolic reprogramming as a key regulator in Helicobacter pylori-infected gastric cancer.
- Neutrophil-Mediated Mechanisms and Therapeutic Reversibility of Gastric Intestinal Metaplasia.
- Simple Postoperative Markers for Early Identification of Low-Risk Patients After Gastric or Colorectal Cancer Surgery: A Retrospective Cohort Study.
- Nanoparticle-Mediated CXCL12-CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma.
- A Novel Liver Metastasis Score for Patients Undergoing Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: A Multi-institutional Study.
- A risk prediction model for gastric cancer based on endoscopic atrophy classification.
- Global, regional, and national burden of gastric cancer attributable to smoking and a high-sodium diet from 1990 to 2021: a global burden of disease study 2021.
- Differentiating the differentiation degree of gastric cancer based on MRI radiomics.
- Associations Between Gastroenteropancreatic Neuroendocrine Neoplasms and Inflammatory Factors: Insights From a Two-Sample Mendelian Randomization Analysis.
- A novel 5'tRNA-derived fragment tRF-Tyr inhibits tumor progression by targeting hnRNPD in gastric cancer.
- ZC3H13 mediates N6-methyladenosine modification of SNTB1 to promote epithelial-mesenchymal transition in gastric cancer.
- MFGE8 promotes gastric cancer progression by activating the IL-6/JAK/STAT3 signaling.
- Defining gastric cancer ecology: the crucial roles of TREM2+ macrophages and fibroblasts in tumor microenvironments.
- A nomogram for predicting the risk of liver metastasis in non-functional neuroendocrine neoplasms: A population-based study.
- Nomogram based on CT imaging and clinical data to predict the efficacy of PD-1 inhibitors combined with chemotherapy in advanced gastric cancer.
- MAZ-mediated LAMA5 transcription activation promotes gastric cancer progression through the STAT3 signaling.
- Hsa_circ_0006837 suppresses gastric cancer cell proliferation, migration, and invasion via the modulation of miR-424-5p.
- ESRP1 exerts anti-tumor role by promoting ferroptosis in diffuse-type gastric cancer.
- Integration of scRNA-seq and ST-seq identifies hyperproliferative RRM2+ cells features and therapeutic targets in gastric cancer.
- Prognostic value of neutrophil-lymphocyte ratio in gastroenteropancreatic neuroendocrine neoplasm: a systematic review and meta-analysis.
- Quercetin induces immunogenic cell death against gastric cancer by targeting NR3C1.
- Molecular characterization and clinical relevance of metabolic signature subtypes in gastric cancer.
- A predictive and prognostic model for metastasis risk and prognostic factors in gastrointestinal signet ring cell carcinoma.
- Safety and effectiveness of totally laparoscopic total gastrectomy vs laparoscopic-assisted total gastrectomy: a meta-analysis.
- Wogonin suppresses proliferation, invasion and migration in gastric cancer cells via targeting the JAK-STAT3 pathway.
- Recurrent Hypoglycemia After Total Gastrectomy: A Case Report and Literature Analysis.
- Tumor microenvironment characteristics association with clinical outcome in patients with resected intestinal-type gastric cancer.
- Correlations between DKI and DWI with Ki-67 in gastric adenocarcinoma.
- TUBA1C: a new potential target of LncRNA EGFR-AS1 promotes gastric cancer progression.
- Helicobacter pylori-induced aberrant demethylation and expression of GNB4 promotes gastric carcinogenesis via the Hippo-YAP1 pathway.
- Targeting Hippo pathway: A novel strategy for Helicobacter pylori-induced gastric cancer treatment.
- Microdissection of cancer-associated fibroblast infiltration subtypes unveils the secreted SERPINE2 contributing to immunosuppressive microenvironment and immuotherapeutic resistance in gastric cancer: A large-scale study integrating bulk a
- CT-based radiomics nomogram for differentiating gastric hepatoid adenocarcinoma from gastric adenocarcinoma: a multicentre study.
- Potential Effects of FGFR4 in the Helicobacter pylori-Induced Inflammatory Carcinoma Transformation.
- Immunotherapy Efficacy-related Risk Classifier Differentiate Prognostic Characteristics of Gastric Cancer-A Large-scale Retrospective Study.
- A case of endocervical adenocarcinoma of the gastric type that was repeatedly misdiagnosed: A case report and literature review.
- Case report: Gastric adenosquamous carcinoma with EBV-positive component of squamous cell carcinoma mixed with gastric carcinoma with lymphoid stroma: A novel case report and literature review.
- High Expression of UPK3A Promotes the Progression of Gastric Cancer Cells by Inactivating p53 Pathway.
- Long-term outcomes of additional surgery after noncurative endoscopic resection in patients with early gastric cancer: A meta-analysis.
- LncRNA RPSAP52 promotes cell proliferation and inhibits cell apoptosis via modulating miR-665/STAT3 in gastric cancer.
- Liquid biopsy in gastric cancer: predictive and prognostic biomarkers.
- A novel 3'tRNA-derived fragment tRF-Val promotes proliferation and inhibits apoptosis by targeting EEF1A1 in gastric cancer.
- Impact of preceding noncurative endoscopic submucosal dissection on patients with early gastric cancer who undergo subsequent surgery: a meta-analysis.
- Statins Are Associated with Improved Survival of Patients with Gastric Cancer: A Systematic Review and Meta-Analysis.
- hsa-miR-875-5p inhibits tumorigenesis and suppresses TGF-β signalling by targeting USF2 in gastric cancer.
- Role of transcribed ultraconserved regions in gastric cancer and therapeutic perspectives.
- LncRNA cancer susceptibility 20 regulates the metastasis of human gastric cancer cells via the miR-143-5p/MEMO1 molecular axis.
- Overall Survival Advantage of Omentum Preservation Over Omentectomy for Advanced Gastric Cancer: A Systematic Review and Meta-Analysis.
- KK-LC-1 may be an effective prognostic biomarker for gastric cancer.
- Prognostic role of tumour-infiltrating lymphocytes assessed by H&E-stained section in gastric cancer: a systematic review and meta-analysis.
- Screening and clinical significance of lymph node metastasis-related genes within esophagogastric junction adenocarcinoma.
- A new candidate oncogenic lncRNA derived from pseudogene WFDC21P promotes tumor progression in gastric cancer.
- The flavonoid Astragalin shows anti-tumor activity and inhibits PI3K/AKT signaling in gastric cancer.
- miR-885-5p Inhibits Invasion and Metastasis in Gastric Cancer by Targeting Malic Enzyme 1.
- CT assessment of preoperative nutritional status in gastric cancer: severe low skeletal muscle mass and obesity-related low skeletal muscle mass are unfavorable factors of postoperative complications.
- Sesquiterpenoid bilobalide inhibits gastric carcinoma cell growth and induces apoptosis both in vitro and in vivo models.
- TNFAIP8 regulates gastric cancer growth via mTOR-Akt-ULK1 pathway and autophagy signals.
- The role and application of small extracellular vesicles in gastric cancer.
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
- Association Between Multiple Coagulation-related Factors and Lymph Node Metastasis in Patients With Gastric Cancer: A Retrospective Cohort Study
- Application of IPC During Surgery to Prevent Venous Thrombosis in Gastrointestinal Surgery Patients.
- Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
- First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
- Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer
- Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer
- First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
- Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 4 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
这些数字背后的记录
牵头的论文3
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 24 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文7
- miR-1343-3p, mediated by LncRNA ASMTL-AS1, induces ferroptosis in osteosarcoma progression by targeting TYRO3.
- Intercalary frozen autografts for reconstruction of bone defects following meta-/diaphyseal tumor resection at the extremities.
- CRISPR/Cas9-mediated overexpression of long non-coding RNA SRY-box transcription factor 21 antisense divergent transcript 1 regulates the proliferation of osteosarcoma by increasing the expression of mechanistic target of rapamycin kinase a
- Identification of Key Genes and miRNAs Affecting Osteosarcoma Based on Bioinformatics.
- The NF-κB pathway is critically implicated in the oncogenic phenotype of human osteosarcoma cells.
- Anticancer effects of melatonin via regulating lncRNA JPX-Wnt/β-catenin signalling pathway in human osteosarcoma cells.
- Melatonin and doxorubicin co-delivered via a functionalized graphene-dendrimeric system enhances apoptosis of osteosarcoma cells.
早期论文(2016–2020 年)12
- CCT128930 induces G1-phase arrest and apoptosis and synergistically enhances the anticancer efficiency of VS5584 in human osteosarcoma cells.
- LncRNA LINC00467 contributes to osteosarcoma growth and metastasis through regulating HMGA1 by directly targeting miR-217.
- MicroRNA-29c-3p inhibits osteosarcoma cell proliferation through targeting PIK3R3.
- Effectiveness of 18F-FDG PET/CT in the diagnosis and staging of osteosarcoma: a meta-analysis of 26 studies.
- miR-522 stimulates TGF-β/Smad signaling pathway and promotes osteosarcoma tumorigenesis by targeting PPM1A.
- Selenocysteine inhibits human osteosarcoma cells growth through triggering mitochondrial dysfunction and ROS-mediated p53 phosphorylation.
- MiR-485-5p inhibits metastasis and proliferation of osteosarcoma by targeting CX3CL1.
- Effectiveness of 18F-FDG PET/CT in the diagnosis, staging and recurrence monitoring of Ewing sarcoma family of tumors: A meta-analysis of 23 studies.
- The prognostic value of PCNA expression in patients with osteosarcoma: A meta-analysis of 16 studies.
- The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.
- Propofol suppresses invasion and induces apoptosis of osteosarcoma cell in vitro via downregulation of TGF-β1 expression.
- Meteorin-Like Shows Unique Expression Pattern in Bone and Its Overexpression Inhibits Osteoblast Differentiation.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
济南有 4 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- 分期
- II/III期
- 开始
- 2026-05
- 登记号
- NCT07379047
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Development of a multi-phase CT-based radiomics model to differentiate heterotopic pancreas from gastrointestinal stromal tumor.
- Naples prognostic score, a novel prognostic score for patients with high- and intermediate-risk gastrointestinal stromal tumours after surgical resection.
- Succinate dehydrogenase deficient gastrointestinal stromal tumor in a three month old boy with a fatal clinical course: a case report and review of literature.
- Association between R1 resection and oncological outcome in resectable gastrointestinal stromal tumors without tumor rupture: A systematic review and meta-analysis.
- Clinicopathological characteristics and longterm survival of patients with synchronous multiple primary gastrointestinal stromal tumors: A propensity score matching analysis.
早期论文(2016–2020 年)4
- miR-4510 acts as a tumor suppressor in gastrointestinal stromal tumor by targeting APOC2.
- Case report of ascending colon cancer and multiple jejunal GISTs in a patient with neurofibromatosis type 1 (NF1).
- Mir-22-3p Enhances the Chemosensitivity of Gastrointestinal Stromal Tumor Cell Lines to Cisplatin through PTEN/PI3K/Akt Pathway.
- A gastrointestinal stromal tumor with acute bleeding: Management and nursing.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 9 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
牵头的论文3
- Diagnostic value of diffusion-weighted magnetic resonance imaging in differentiating benign and malignant fetal adrenal tumors.
- MiR-99b regulates cerebral ischemia neuronal injury through targeting IGF1R.
- Aberrant expression of LINC00346 regulates cell migration and proliferation via competitively binding to miRNA-148a-3p/Dnmt1 in Hirschsprung's disease.
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 5 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.4%。
- 牵头的开放试验
- 0
- 正在或即将招募
济南有 7 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- 分期
- I期
- 开始
- 2026-05
- 登记号
- NCT07477587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛
- 正在招募Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- 分期
- IV期
- 开始
- 2023-10
- 登记号
- NCT06057402
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、广州、杭州、济南
- 正在招募A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- 分期
- III期
- 开始
- 2021-10
- 登记号
- NCT05020236
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春
- 即将招募Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-06
- 登记号
- NCT07569757
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文6
- Multiple myeloma in a man with breast cancer: A case report and literature review.
- The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).
- Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study.
- An MRI-based radiomics nomogram for differentiating spinal metastases from multiple myeloma.
- Role of ncRNA in multiple myeloma.
- BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 2 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。
血液疾病
再生障碍性贫血
Aplastic anaemia2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 6 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。
这些数字背后的记录
牵头的论文4
- Pan-cancer analysis of the tumorigenic role of Fanconi anemia complementation group D2 (FANCD2) in human tumors.
- Novel compound heterozygous variants in FANCI cause premature ovarian insufficiency.
- The ratio of bone marrow myeloid progenitor cell proportion to mature lymphocytes proportion can effectively differentiate aplastic anemia and hypoplastic myelodysplastic syndrome and evaluate the quality of bone marrow aspirates.
- Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine.
血液疾病
非典型溶血性尿毒症综合征
Atypical haemolytic uraemic syndrome2021–2025 年中国大陆作者发表的 27 篇非典型溶血性尿毒症综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 1 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。
血液疾病
范可尼贫血
Fanconi anaemia2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 3 篇,占 4.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。
这些数字背后的记录
牵头的论文3
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 3 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 4 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。
这些数字背后的记录
牵头的论文3
- Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
- Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis With Peripheral Nerve Hyperexcitability: Case Report and Literature Review.
- Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients.
其他疾病
肝豆状核变性
Wilson disease2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 1 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝豆状核变性开放试验。
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 8 篇,占 3.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 5 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
这些数字背后的记录
牵头的论文8
- Combination therapy of ofatumumab and daratumumab in patients with severe anti-NMDA receptor encephalitis.
- Successful sequential therapy with rituximab and telitacicept in refractory Anti-NMDA receptor encephalitis and MOG-associated demyelination: a case report and literature review.
- Low-dose rituximab for the treatment of anti-NMDAR encephalitis in children: a case series study.
- Effectiveness of Anti-CD20 B cells depleting therapy versus conventional treatment in severe Anti-N-methyl-d-aspartate receptor encephalitis: A real-world multi-center prospective cohort study.
- Clinical characteristics and prognosis in patients with neuronal surface antibody-mediated autoimmune encephalitis: a single-center cohort study in China.
- Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: An observational study.
- Lipid profiles and their potential inflammatory effects in anti-N-methyl-D-aspartate receptor encephalitis.
- High serum creatinine is associated with reduction of psychiatric symptoms in female patients with anti-NMDAR encephalitis.
早期论文(2016–2020 年)4
- The differential expression and potential roles of circular RNAs in children with anti-NMDA receptor encephalitis.
- Clinical features of adult anti-N-methyl-d-aspartate receptor encephalitis after Japanese encephalitis.
- The short-term efficacy of combined treatments targeting B cell and plasma cell in severe and refractory Anti-N-methyl-D-aspartate receptor encephalitis: Two case reports.
- Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour.
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 2 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
这些数字背后的记录
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 9 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
牵头的论文3
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 8 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
这些数字背后的记录
其他疾病
法布雷病
Fabry disease2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 3 家医院列在法布雷病下全国有 85 家医院列在法布雷病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
庞贝病
Pompe disease2021–2025 年中国大陆作者发表的 30 篇庞贝病 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 2 家医院列在庞贝病下全国有 30 家医院列在庞贝病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 2 家医院列在白塞病下全国有 149 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
这些数字背后的记录
牵头的论文2
- Long-term efficacy, safety, and cumulative retention rate of antitumor necrosis factor-alpha treatment for patients with Behcet's uveitis: A systematic review and meta-analysis.
- Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet's Disease: A Systematic Review and Meta-Analysis.
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 12 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
牵头的论文3
- Associations of left renal vein entrapment with IgA nephropathy and Henoch-Schönlein purpura nephritis.
- A simple nomogram for assessing the risk of IgA vasculitis nephritis in IgA vasculitis Asian pediatric patients.
- Coexisting nutcracker phenomenon and superior mesenteric artery syndrome in a patient with IgA nephropathy: A case report.
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
其他疾病
成骨不全症
Osteogenesis imperfecta2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 6 篇,占 6.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 2 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。
这些数字背后的记录
牵头的论文6
- Endoplasmic reticulum stress and autophagy as potential therapeutic targets in SERPINF1 mutation-induced type VI osteogenesis imperfecta.
- Voices of Parent-Carers Navigating the Care for Children With Osteogenesis Imperfecta.
- Home care needs assessment among caregivers of children and adolescents with osteogenesis imperfecta: a cross-sectional study.
- Risk perception for fractures and its related factors among family caregivers of underage patients with osteogenesis imperfecta in China: A cross-sectional study.
- Pathogenic mechanisms of osteogenesis imperfecta, evidence for classification.
- Genotype-Phenotype Relationship and Follow-up Analysis of a Chinese Cohort With Osteogenesis Imperfecta.
早期论文(2016–2020 年)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 7 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
先天性巨结肠
Hirschsprung disease2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 5 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。
这些数字背后的记录
牵头的论文3
- Proteomic Analysis Provides a New Sight Into the CRABP1 Expression in the Pathogenesis of Hirschsprung Disease.
- Aberrant expression of LINC00346 regulates cell migration and proliferation via competitively binding to miRNA-148a-3p/Dnmt1 in Hirschsprung's disease.
- MiR-195-5p inhibits proliferation and invasion of nerve cells in Hirschsprung disease by targeting GFRA4.
早期论文(2016–2020 年)3
- Downregulation of miR-140-5p affects the pathogenesis of HSCR by targeting EGR2.
- Enteric Neural Stem Cells Expressing Insulin-Like Growth Factor 1: A Novel Cellular Therapy for Hirschsprung's Disease in Mouse Model.
- Demethylation of GFRA4 Promotes Cell Proliferation and Invasion in Hirschsprung Disease.
其他疾病
遗传性大疱性表皮松解症
Inherited epidermolysis bullosa2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
济南有 1 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。
这些数字背后的记录
联系这家医院
出示给工作人员或司机的院名卡
山东省立医院
Shandong Provincial Hospital
济南
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
Shandong Provincial Hospital Affiliated to Shandong University; Shandong Provincial Hospital of Traditional Chinese Medicine; Shandong Provincial Hospital Affiliated; Shandong Provincial Hospital Affiliated Shandong University; Shandong Provincial Hospital affiliated to Cheeloo College of Medicine; Cancer Center of Shandong Provincial Hospital; Shandong Provincial Hospital affiliated to; Shandong Provincial Hospital Heze Branch